 Michael Arnold
Concepts (552)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdomyosarcoma | 12 | 2025 | 72 | 3.050 |
Why?
| | Cancer Survivors | 20 | 2025 | 285 | 2.470 |
Why?
| | Neoplasms, Second Primary | 11 | 2025 | 118 | 1.630 |
Why?
| | Wilms Tumor | 4 | 2022 | 86 | 1.380 |
Why?
| | Desmoplastic Small Round Cell Tumor | 3 | 2022 | 6 | 1.370 |
Why?
| | Sarcoma | 6 | 2024 | 188 | 1.360 |
Why?
| | Sarcoma, Ewing | 4 | 2022 | 97 | 1.320 |
Why?
| | Bone Neoplasms | 5 | 2024 | 247 | 1.250 |
Why?
| | Biomarkers, Tumor | 8 | 2025 | 1276 | 1.230 |
Why?
| | Kidney Neoplasms | 5 | 2022 | 403 | 1.160 |
Why?
| | Neoplasms | 14 | 2025 | 2671 | 1.080 |
Why?
| | Pathology, Clinical | 2 | 2024 | 36 | 1.030 |
Why?
| | Thyroid Neoplasms | 6 | 2024 | 343 | 1.000 |
Why?
| | Immunohistochemistry | 7 | 2025 | 1738 | 1.000 |
Why?
| | Hirschsprung Disease | 6 | 2025 | 88 | 0.980 |
Why?
| | Rhabdomyosarcoma, Embryonal | 5 | 2025 | 22 | 0.950 |
Why?
| | Oncogene Proteins, Fusion | 7 | 2022 | 215 | 0.910 |
Why?
| | Child | 58 | 2025 | 21935 | 0.870 |
Why?
| | Rhabdomyosarcoma, Alveolar | 4 | 2023 | 11 | 0.860 |
Why?
| | Carcinoma, Basal Cell | 4 | 2025 | 75 | 0.770 |
Why?
| | Pediatrics | 2 | 2024 | 1101 | 0.760 |
Why?
| | Soft Tissue Neoplasms | 4 | 2025 | 115 | 0.750 |
Why?
| | Gene Fusion | 3 | 2020 | 27 | 0.740 |
Why?
| | Skin Neoplasms | 5 | 2025 | 855 | 0.740 |
Why?
| | Gastritis | 3 | 2024 | 108 | 0.720 |
Why?
| | Artificial Intelligence | 1 | 2024 | 279 | 0.710 |
Why?
| | Myogenic Regulatory Factors | 8 | 2009 | 57 | 0.700 |
Why?
| | Child, Preschool | 33 | 2025 | 11074 | 0.660 |
Why?
| | Breast Neoplasms | 8 | 2025 | 2253 | 0.650 |
Why?
| | Infant | 27 | 2025 | 9465 | 0.630 |
Why?
| | Gallbladder Diseases | 1 | 2019 | 12 | 0.620 |
Why?
| | Inclusion Bodies | 1 | 2019 | 28 | 0.620 |
Why?
| | Adolescent | 43 | 2025 | 21513 | 0.610 |
Why?
| | Pyridines | 3 | 2022 | 506 | 0.590 |
Why?
| | Rectum | 5 | 2025 | 185 | 0.580 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2024 | 267 | 0.580 |
Why?
| | Azabicyclo Compounds | 1 | 2017 | 6 | 0.560 |
Why?
| | Niacin | 1 | 2017 | 17 | 0.560 |
Why?
| | Sarcoma, Synovial | 2 | 2018 | 21 | 0.550 |
Why?
| | Neoplasms, Radiation-Induced | 5 | 2021 | 92 | 0.540 |
Why?
| | Humans | 94 | 2025 | 137585 | 0.530 |
Why?
| | Biopsy | 10 | 2025 | 1129 | 0.530 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1809 | 0.530 |
Why?
| | Helicobacter | 1 | 2016 | 4 | 0.530 |
Why?
| | Helicobacter Infections | 1 | 2016 | 32 | 0.520 |
Why?
| | Stomach | 1 | 2016 | 110 | 0.510 |
Why?
| | Young Adult | 30 | 2025 | 13209 | 0.510 |
Why?
| | Carbodiimides | 2 | 2006 | 4 | 0.500 |
Why?
| | Imines | 2 | 2006 | 8 | 0.500 |
Why?
| | Alkaloids | 2 | 2006 | 30 | 0.490 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 105 | 0.490 |
Why?
| | Chromosomal Proteins, Non-Histone | 2 | 2013 | 126 | 0.470 |
Why?
| | Female | 65 | 2025 | 73304 | 0.460 |
Why?
| | Colestipol | 1 | 2014 | 1 | 0.460 |
Why?
| | Ion Exchange Resins | 1 | 2014 | 5 | 0.460 |
Why?
| | Frozen Sections | 1 | 2015 | 26 | 0.460 |
Why?
| | Allylamine | 1 | 2014 | 8 | 0.460 |
Why?
| | Thyroid Diseases | 1 | 2015 | 36 | 0.460 |
Why?
| | Pathology, Surgical | 1 | 2014 | 10 | 0.460 |
Why?
| | Intestines | 2 | 2015 | 357 | 0.460 |
Why?
| | Biopsy, Fine-Needle | 1 | 2015 | 68 | 0.450 |
Why?
| | Colon | 4 | 2025 | 282 | 0.450 |
Why?
| | Thyroid Gland | 1 | 2015 | 94 | 0.440 |
Why?
| | S100 Proteins | 1 | 2014 | 37 | 0.440 |
Why?
| | Transcription Factors | 6 | 2017 | 1719 | 0.440 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 65 | 0.440 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1587 | 0.420 |
Why?
| | Cerebral Ventricle Neoplasms | 1 | 2013 | 4 | 0.410 |
Why?
| | Male | 53 | 2025 | 67762 | 0.410 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2013 | 16 | 0.410 |
Why?
| | Specimen Handling | 1 | 2014 | 183 | 0.410 |
Why?
| | Survivors | 3 | 2025 | 493 | 0.400 |
Why?
| | Anticholesteremic Agents | 1 | 2014 | 153 | 0.400 |
Why?
| | Risk Factors | 20 | 2025 | 10388 | 0.390 |
Why?
| | DNA-Binding Proteins | 4 | 2013 | 1502 | 0.370 |
Why?
| | Adult | 37 | 2025 | 37929 | 0.370 |
Why?
| | Retrospective Studies | 21 | 2025 | 15657 | 0.360 |
Why?
| | Incidence | 12 | 2025 | 2804 | 0.360 |
Why?
| | DNA | 2 | 2017 | 1459 | 0.350 |
Why?
| | Societies, Medical | 1 | 2014 | 820 | 0.330 |
Why?
| | Guideline Adherence | 1 | 2014 | 556 | 0.330 |
Why?
| | Guanidines | 2 | 2006 | 39 | 0.320 |
Why?
| | Risk Assessment | 9 | 2025 | 3457 | 0.320 |
Why?
| | Diagnosis, Differential | 6 | 2025 | 1483 | 0.310 |
Why?
| | Prognosis | 11 | 2025 | 4030 | 0.310 |
Why?
| | WT1 Proteins | 2 | 2022 | 15 | 0.300 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1692 | 0.300 |
Why?
| | Paired Box Transcription Factors | 3 | 2020 | 46 | 0.300 |
Why?
| | Predictive Value of Tests | 6 | 2017 | 2031 | 0.290 |
Why?
| | Radiotherapy | 4 | 2025 | 201 | 0.280 |
Why?
| | Gram-Negative Bacteria | 2 | 2018 | 73 | 0.280 |
Why?
| | Bone Development | 1 | 2007 | 54 | 0.260 |
Why?
| | Pyrimidines | 2 | 2006 | 470 | 0.250 |
Why?
| | Bone and Bones | 2 | 2018 | 317 | 0.250 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2025 | 12 | 0.240 |
Why?
| | Intestinal Mucosa | 4 | 2019 | 623 | 0.240 |
Why?
| | Vinyl Compounds | 1 | 2005 | 6 | 0.240 |
Why?
| | Guanidine | 1 | 2005 | 21 | 0.240 |
Why?
| | Cartilage | 1 | 2007 | 188 | 0.240 |
Why?
| | Antineoplastic Agents | 4 | 2022 | 2129 | 0.230 |
Why?
| | Clinical Trials as Topic | 3 | 2020 | 1050 | 0.230 |
Why?
| | Cranial Irradiation | 1 | 2025 | 70 | 0.230 |
Why?
| | Chondrocytes | 1 | 2007 | 212 | 0.230 |
Why?
| | Forkhead Box Protein O1 | 2 | 2024 | 33 | 0.230 |
Why?
| | Calcium Sulfate | 1 | 2024 | 1 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 4 | 2020 | 2426 | 0.220 |
Why?
| | Carcinoma, Renal Cell | 2 | 2020 | 217 | 0.220 |
Why?
| | Middle Aged | 21 | 2025 | 33479 | 0.220 |
Why?
| | Eosinophilia | 2 | 2024 | 218 | 0.220 |
Why?
| | Pathology | 1 | 2024 | 24 | 0.220 |
Why?
| | Duodenitis | 1 | 2024 | 7 | 0.220 |
Why?
| | Vincristine | 1 | 2024 | 116 | 0.210 |
Why?
| | Polyketides | 1 | 2023 | 3 | 0.210 |
Why?
| | Infant, Newborn | 10 | 2022 | 6079 | 0.210 |
Why?
| | Cyclophosphamide | 1 | 2024 | 247 | 0.210 |
Why?
| | Mutation | 5 | 2021 | 3958 | 0.210 |
Why?
| | Education, Distance | 1 | 2024 | 50 | 0.210 |
Why?
| | Vancomycin | 1 | 2024 | 84 | 0.210 |
Why?
| | Dysautonomia, Familial | 1 | 2023 | 2 | 0.210 |
Why?
| | Disease-Free Survival | 4 | 2020 | 686 | 0.200 |
Why?
| | Prosthesis-Related Infections | 1 | 2024 | 95 | 0.200 |
Why?
| | Orbital Neoplasms | 1 | 2023 | 24 | 0.200 |
Why?
| | Enterocolitis | 1 | 2023 | 17 | 0.200 |
Why?
| | Microbial Sensitivity Tests | 3 | 2022 | 361 | 0.200 |
Why?
| | Central Nervous System Neoplasms | 1 | 2025 | 156 | 0.200 |
Why?
| | Survival Rate | 6 | 2025 | 1972 | 0.200 |
Why?
| | Eyelids | 1 | 2023 | 37 | 0.200 |
Why?
| | Retinal Degeneration | 1 | 2023 | 38 | 0.200 |
Why?
| | SMARCB1 Protein | 2 | 2013 | 31 | 0.200 |
Why?
| | Mice | 18 | 2024 | 17787 | 0.200 |
Why?
| | Age Factors | 5 | 2019 | 3295 | 0.190 |
Why?
| | Sirolimus | 1 | 2024 | 276 | 0.190 |
Why?
| | Leukemia | 1 | 2024 | 240 | 0.190 |
Why?
| | Bone Marrow | 1 | 2023 | 286 | 0.190 |
Why?
| | Telomere Homeostasis | 2 | 2020 | 34 | 0.190 |
Why?
| | Norwood Procedures | 1 | 2022 | 29 | 0.190 |
Why?
| | Ribonucleotide Reductases | 1 | 2022 | 31 | 0.190 |
Why?
| | Muscle Proteins | 3 | 2017 | 231 | 0.190 |
Why?
| | Telomere Shortening | 1 | 2021 | 20 | 0.190 |
Why?
| | MEF2 Transcription Factors | 8 | 2009 | 61 | 0.190 |
Why?
| | Vulvar Neoplasms | 1 | 2021 | 13 | 0.190 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.180 |
Why?
| | Appendix | 1 | 2021 | 30 | 0.180 |
Why?
| | Alphapapillomavirus | 1 | 2021 | 39 | 0.180 |
Why?
| | Radiation Dosage | 2 | 2019 | 179 | 0.180 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 872 | 0.180 |
Why?
| | Histone Deacetylases | 3 | 2007 | 215 | 0.180 |
Why?
| | MyoD Protein | 2 | 2021 | 35 | 0.180 |
Why?
| | Gonorrhea | 1 | 2022 | 59 | 0.180 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2022 | 121 | 0.170 |
Why?
| | Kaplan-Meier Estimate | 3 | 2023 | 889 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 135 | 0.170 |
Why?
| | Biliary Tract Neoplasms | 1 | 2021 | 30 | 0.170 |
Why?
| | Schwann Cells | 1 | 2020 | 34 | 0.170 |
Why?
| | Combined Modality Therapy | 3 | 2025 | 1236 | 0.170 |
Why?
| | Drug Resistance, Bacterial | 1 | 2022 | 186 | 0.170 |
Why?
| | Colonic Neoplasms | 2 | 2013 | 258 | 0.170 |
Why?
| | Chromosome Breakpoints | 1 | 2020 | 8 | 0.170 |
Why?
| | Rhabdomyoma | 1 | 2020 | 8 | 0.170 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2018 | 184 | 0.170 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2020 | 25 | 0.170 |
Why?
| | Colitis, Ischemic | 1 | 2019 | 6 | 0.160 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 434 | 0.160 |
Why?
| | Colitis | 2 | 2021 | 266 | 0.160 |
Why?
| | Cohort Studies | 8 | 2024 | 5742 | 0.160 |
Why?
| | Histones | 1 | 2025 | 636 | 0.160 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2020 | 43 | 0.160 |
Why?
| | Heart Neoplasms | 1 | 2020 | 50 | 0.160 |
Why?
| | Diagnostic Errors | 3 | 2017 | 170 | 0.160 |
Why?
| | Structure-Activity Relationship | 2 | 2018 | 570 | 0.160 |
Why?
| | Carcinoid Tumor | 1 | 2019 | 26 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2021 | 2189 | 0.160 |
Why?
| | Appendiceal Neoplasms | 1 | 2019 | 27 | 0.160 |
Why?
| | Staphylococcal Infections | 1 | 2024 | 400 | 0.160 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5131 | 0.160 |
Why?
| | Machine Learning | 1 | 2024 | 493 | 0.160 |
Why?
| | Head and Neck Neoplasms | 1 | 2025 | 606 | 0.160 |
Why?
| | Gallbladder | 1 | 2019 | 19 | 0.160 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3284 | 0.160 |
Why?
| | Colitis, Ulcerative | 1 | 2021 | 136 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 1079 | 0.150 |
Why?
| | Phenotype | 5 | 2015 | 3196 | 0.150 |
Why?
| | Research Report | 1 | 2019 | 83 | 0.150 |
Why?
| | Neurofibromatosis 1 | 1 | 2019 | 52 | 0.150 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2019 | 20 | 0.150 |
Why?
| | Neurogenesis | 1 | 2020 | 149 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2020 | 528 | 0.150 |
Why?
| | Enteric Nervous System | 1 | 2019 | 23 | 0.150 |
Why?
| | Neural Stem Cells | 1 | 2020 | 156 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2024 | 683 | 0.150 |
Why?
| | Cholecystectomy | 1 | 2019 | 62 | 0.150 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 77 | 0.150 |
Why?
| | Vagina | 1 | 2021 | 187 | 0.150 |
Why?
| | Glucose Transporter Type 1 | 1 | 2018 | 50 | 0.150 |
Why?
| | Gene Rearrangement | 2 | 2022 | 150 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2019 | 145 | 0.150 |
Why?
| | Anal Canal | 1 | 2019 | 97 | 0.150 |
Why?
| | Ohio | 2 | 2017 | 152 | 0.150 |
Why?
| | Telomere-Binding Proteins | 1 | 2020 | 122 | 0.150 |
Why?
| | Choice Behavior | 1 | 2020 | 170 | 0.140 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2018 | 25 | 0.140 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2018 | 45 | 0.140 |
Why?
| | Nanoparticles | 2 | 2015 | 481 | 0.140 |
Why?
| | Digestive System Surgical Procedures | 1 | 2019 | 106 | 0.140 |
Why?
| | Prospective Studies | 5 | 2021 | 7604 | 0.140 |
Why?
| | Epithelium | 1 | 2019 | 313 | 0.140 |
Why?
| | Age of Onset | 1 | 2019 | 518 | 0.140 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2018 | 78 | 0.140 |
Why?
| | Animals | 18 | 2024 | 36940 | 0.140 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 452 | 0.140 |
Why?
| | Eosinophilic Esophagitis | 1 | 2022 | 325 | 0.140 |
Why?
| | Half-Life | 1 | 2017 | 164 | 0.140 |
Why?
| | Povidone | 1 | 2017 | 5 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1396 | 0.140 |
Why?
| | Escherichia coli | 2 | 2022 | 815 | 0.140 |
Why?
| | Immunocompromised Host | 1 | 2019 | 202 | 0.140 |
Why?
| | Proportional Hazards Models | 4 | 2024 | 1266 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 190 | 0.140 |
Why?
| | Nephroma, Mesoblastic | 1 | 2017 | 3 | 0.140 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2017 | 46 | 0.140 |
Why?
| | Interleukin-8 | 1 | 2018 | 268 | 0.140 |
Why?
| | Curriculum | 1 | 2024 | 992 | 0.130 |
Why?
| | Computer Communication Networks | 1 | 2017 | 33 | 0.130 |
Why?
| | Nuclear Receptor Coactivator 1 | 1 | 2017 | 11 | 0.130 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.130 |
Why?
| | Drug Discovery | 1 | 2018 | 142 | 0.130 |
Why?
| | Excipients | 1 | 2017 | 55 | 0.130 |
Why?
| | Cellulose | 1 | 2017 | 39 | 0.130 |
Why?
| | Glioma | 1 | 2021 | 395 | 0.130 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 225 | 0.130 |
Why?
| | Candidiasis | 1 | 2017 | 56 | 0.130 |
Why?
| | Body Mass Index | 1 | 2025 | 2389 | 0.130 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 351 | 0.130 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4295 | 0.130 |
Why?
| | United States | 9 | 2025 | 14841 | 0.130 |
Why?
| | Esophagitis | 1 | 2017 | 67 | 0.130 |
Why?
| | Enterocolitis, Neutropenic | 1 | 2015 | 6 | 0.120 |
Why?
| | Stereoisomerism | 2 | 2006 | 96 | 0.120 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 8 | 0.120 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 14 | 0.120 |
Why?
| | beta 2-Microglobulin | 1 | 2015 | 50 | 0.120 |
Why?
| | Virus Internalization | 1 | 2015 | 49 | 0.120 |
Why?
| | Canada | 3 | 2025 | 418 | 0.120 |
Why?
| | Heart Transplantation | 1 | 2022 | 754 | 0.120 |
Why?
| | Receptors, Virus | 1 | 2015 | 83 | 0.120 |
Why?
| | Sarcoma, Experimental | 1 | 2015 | 7 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 976 | 0.120 |
Why?
| | Granuloma, Foreign-Body | 1 | 2015 | 10 | 0.120 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 13 | 0.120 |
Why?
| | Cholestyramine Resin | 1 | 2014 | 7 | 0.120 |
Why?
| | Colesevelam Hydrochloride | 1 | 2014 | 8 | 0.120 |
Why?
| | Information Dissemination | 1 | 2017 | 218 | 0.110 |
Why?
| | Desmin | 1 | 2014 | 24 | 0.110 |
Why?
| | Herpesvirus 1, Human | 1 | 2015 | 87 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2016 | 317 | 0.110 |
Why?
| | Immunotherapy | 2 | 2018 | 641 | 0.110 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 195 | 0.110 |
Why?
| | Albumins | 1 | 2015 | 114 | 0.110 |
Why?
| | Anthracyclines | 2 | 2025 | 42 | 0.110 |
Why?
| | Neuroblastoma | 1 | 2015 | 160 | 0.110 |
Why?
| | Cardiac Surgical Procedures | 1 | 2020 | 530 | 0.110 |
Why?
| | Thyroidectomy | 1 | 2015 | 106 | 0.110 |
Why?
| | Quality Control | 1 | 2014 | 172 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 203 | 0.110 |
Why?
| | Cerebral Ventricles | 1 | 2014 | 52 | 0.110 |
Why?
| | Interleukin-6 | 1 | 2018 | 778 | 0.110 |
Why?
| | Social Media | 1 | 2017 | 158 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 804 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 77 | 0.110 |
Why?
| | Keratins | 1 | 2014 | 173 | 0.110 |
Why?
| | Time Factors | 5 | 2025 | 6828 | 0.110 |
Why?
| | Paclitaxel | 1 | 2015 | 230 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2020 | 786 | 0.110 |
Why?
| | Tubulin | 1 | 2015 | 144 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 591 | 0.110 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2014 | 66 | 0.110 |
Why?
| | Exercise | 1 | 2025 | 2057 | 0.100 |
Why?
| | Ganglioneuroma | 1 | 2013 | 2 | 0.100 |
Why?
| | Ileal Neoplasms | 1 | 2013 | 3 | 0.100 |
Why?
| | Vascular Malformations | 1 | 2014 | 52 | 0.100 |
Why?
| | Food | 1 | 2015 | 164 | 0.100 |
Why?
| | Glucose-6-Phosphatase | 1 | 2013 | 33 | 0.100 |
Why?
| | Muscle, Skeletal | 4 | 2007 | 1724 | 0.100 |
Why?
| | MicroRNAs | 1 | 2020 | 692 | 0.100 |
Why?
| | Cerebral Hemorrhage | 1 | 2014 | 108 | 0.100 |
Why?
| | Microscopy | 1 | 2014 | 152 | 0.100 |
Why?
| | Calcium Phosphates | 1 | 2013 | 27 | 0.100 |
Why?
| | Hypertrophy | 2 | 2018 | 133 | 0.100 |
Why?
| | Repressor Proteins | 2 | 2006 | 427 | 0.100 |
Why?
| | Lateral Ventricles | 1 | 2013 | 35 | 0.100 |
Why?
| | Human Growth Hormone | 1 | 2013 | 48 | 0.100 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2013 | 57 | 0.100 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 156 | 0.100 |
Why?
| | Treatment Outcome | 5 | 2022 | 10811 | 0.100 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 209 | 0.100 |
Why?
| | COS Cells | 3 | 2007 | 188 | 0.100 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2013 | 54 | 0.100 |
Why?
| | Neutropenia | 1 | 2013 | 146 | 0.100 |
Why?
| | Cell Line, Tumor | 5 | 2019 | 3412 | 0.090 |
Why?
| | Endocytosis | 1 | 2013 | 172 | 0.090 |
Why?
| | Sepsis | 1 | 2018 | 617 | 0.090 |
Why?
| | Enteritis | 2 | 2024 | 103 | 0.090 |
Why?
| | Patient Selection | 1 | 2015 | 696 | 0.090 |
Why?
| | Colonic Polyps | 1 | 2013 | 88 | 0.090 |
Why?
| | Spinal Cord | 1 | 2014 | 370 | 0.090 |
Why?
| | Rhabdoid Tumor | 1 | 2012 | 99 | 0.090 |
Why?
| | North America | 2 | 2024 | 313 | 0.090 |
Why?
| | Neurosurgical Procedures | 1 | 2013 | 197 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2011 | 125 | 0.090 |
Why?
| | Feasibility Studies | 1 | 2014 | 956 | 0.080 |
Why?
| | Adenoma | 1 | 2013 | 230 | 0.080 |
Why?
| | Colonoscopy | 1 | 2013 | 245 | 0.080 |
Why?
| | Aged | 7 | 2024 | 23961 | 0.080 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 622 | 0.080 |
Why?
| | Recurrence | 3 | 2024 | 1060 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1238 | 0.080 |
Why?
| | Constipation | 2 | 2023 | 94 | 0.080 |
Why?
| | Sarcomeres | 2 | 2007 | 96 | 0.080 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2009 | 7 | 0.080 |
Why?
| | SEER Program | 2 | 2021 | 227 | 0.080 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2007 | 218 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2021 | 2844 | 0.070 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2009 | 70 | 0.070 |
Why?
| | Residence Characteristics | 1 | 2011 | 351 | 0.070 |
Why?
| | Coccidioidomycosis | 1 | 2008 | 7 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 55 | 0.070 |
Why?
| | Risk | 2 | 2021 | 912 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1946 | 0.070 |
Why?
| | Waste Disposal, Fluid | 1 | 2008 | 49 | 0.070 |
Why?
| | Cell Proliferation | 3 | 2018 | 2475 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2013 | 641 | 0.070 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2007 | 860 | 0.070 |
Why?
| | Doxorubicin | 2 | 2023 | 362 | 0.070 |
Why?
| | Dwarfism | 1 | 2007 | 17 | 0.070 |
Why?
| | Pressure | 1 | 2008 | 225 | 0.070 |
Why?
| | Mice, Transgenic | 3 | 2007 | 2167 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 148 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2021 | 3556 | 0.060 |
Why?
| | Gastroschisis | 1 | 2006 | 29 | 0.060 |
Why?
| | Colectomy | 2 | 2019 | 100 | 0.060 |
Why?
| | Actinin | 1 | 2006 | 13 | 0.060 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2005 | 6 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2007 | 179 | 0.060 |
Why?
| | Alkylation | 1 | 2005 | 26 | 0.060 |
Why?
| | Osteogenesis | 1 | 2007 | 188 | 0.060 |
Why?
| | Cell Differentiation | 3 | 2008 | 1991 | 0.060 |
Why?
| | Neoplastic Stem Cells | 1 | 2009 | 399 | 0.060 |
Why?
| | HIV Infections | 1 | 2020 | 2836 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2526 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1250 | 0.060 |
Why?
| | Molecular Sequence Data | 5 | 2007 | 2900 | 0.060 |
Why?
| | Genome-Wide Association Study | 2 | 2024 | 1431 | 0.060 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 674 | 0.060 |
Why?
| | Dactinomycin | 1 | 2024 | 28 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 767 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2020 | 1389 | 0.060 |
Why?
| | Base Sequence | 4 | 2013 | 2181 | 0.060 |
Why?
| | Mastectomy | 1 | 2025 | 137 | 0.050 |
Why?
| | Molecular Medicine | 1 | 2024 | 2 | 0.050 |
Why?
| | Bacterial Load | 1 | 2024 | 68 | 0.050 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2006 | 261 | 0.050 |
Why?
| | Knee Prosthesis | 1 | 2024 | 27 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2017 | 7635 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 554 | 0.050 |
Why?
| | Daunorubicin | 1 | 2023 | 26 | 0.050 |
Why?
| | Podophyllotoxin | 1 | 2023 | 7 | 0.050 |
Why?
| | Public Opinion | 1 | 2024 | 65 | 0.050 |
Why?
| | Random Allocation | 1 | 2024 | 353 | 0.050 |
Why?
| | Kinetin | 1 | 2023 | 1 | 0.050 |
Why?
| | Gait Ataxia | 1 | 2023 | 4 | 0.050 |
Why?
| | Keratinocytes | 1 | 2024 | 249 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 346 | 0.050 |
Why?
| | Breast | 1 | 2023 | 151 | 0.050 |
Why?
| | Necrosis | 1 | 2023 | 246 | 0.050 |
Why?
| | Deoxyadenine Nucleotides | 1 | 2022 | 14 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1996 | 0.050 |
Why?
| | Neisseria gonorrhoeae | 1 | 2022 | 26 | 0.050 |
Why?
| | Allosteric Regulation | 1 | 2022 | 97 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.050 |
Why?
| | Mice, SCID | 2 | 2015 | 367 | 0.050 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2024 | 228 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2023 | 234 | 0.050 |
Why?
| | Placenta | 1 | 2008 | 750 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 771 | 0.050 |
Why?
| | Educational Measurement | 1 | 2024 | 289 | 0.040 |
Why?
| | Haploinsufficiency | 1 | 2021 | 56 | 0.040 |
Why?
| | Colon, Sigmoid | 1 | 2021 | 20 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 194 | 0.040 |
Why?
| | Papillomaviridae | 1 | 2021 | 125 | 0.040 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 99 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2025 | 447 | 0.040 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 63 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 182 | 0.040 |
Why?
| | Cloaca | 1 | 2021 | 48 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 307 | 0.040 |
Why?
| | Administration, Oral | 1 | 2023 | 816 | 0.040 |
Why?
| | Myocardium | 1 | 2006 | 1002 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2021 | 220 | 0.040 |
Why?
| | France | 1 | 2020 | 33 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 133 | 0.040 |
Why?
| | Transcription Initiation Site | 1 | 2020 | 43 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2007 | 2607 | 0.040 |
Why?
| | Genes, ras | 1 | 2020 | 97 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 2021 | 245 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2024 | 450 | 0.040 |
Why?
| | Hepatocyte Growth Factor | 1 | 2019 | 35 | 0.040 |
Why?
| | Genomic Instability | 1 | 2020 | 53 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 89 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2019 | 141 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2023 | 506 | 0.040 |
Why?
| | Eosinophils | 1 | 2022 | 332 | 0.040 |
Why?
| | Internet | 1 | 2024 | 655 | 0.040 |
Why?
| | Students, Medical | 1 | 2024 | 348 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2019 | 268 | 0.040 |
Why?
| | Mice, Knockout | 4 | 2007 | 3015 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2019 | 75 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2019 | 81 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2013 | 327 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2022 | 1272 | 0.040 |
Why?
| | Anorectal Malformations | 1 | 2020 | 112 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 309 | 0.040 |
Why?
| | Tissue Donors | 1 | 2022 | 425 | 0.040 |
Why?
| | Receptors, Interleukin-8A | 1 | 2018 | 6 | 0.040 |
Why?
| | Cytokine Receptor gp130 | 1 | 2018 | 12 | 0.040 |
Why?
| | Introns | 1 | 2020 | 258 | 0.040 |
Why?
| | Diarrhea | 1 | 2019 | 184 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 622 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 521 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2019 | 242 | 0.040 |
Why?
| | Abdominal Pain | 1 | 2019 | 145 | 0.040 |
Why?
| | Hydrazines | 1 | 2018 | 35 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2019 | 268 | 0.040 |
Why?
| | Quinoxalines | 1 | 2018 | 66 | 0.040 |
Why?
| | Appendicitis | 1 | 2019 | 130 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2018 | 171 | 0.040 |
Why?
| | Algorithms | 1 | 2025 | 1704 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2018 | 74 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2018 | 173 | 0.030 |
Why?
| | Genetic Loci | 1 | 2019 | 288 | 0.030 |
Why?
| | Mice, Mutant Strains | 2 | 2008 | 298 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2018 | 318 | 0.030 |
Why?
| | Up-Regulation | 1 | 2020 | 843 | 0.030 |
Why?
| | Leukocytes | 1 | 2018 | 311 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 978 | 0.030 |
Why?
| | Molecular Structure | 1 | 2018 | 489 | 0.030 |
Why?
| | HLA Antigens | 1 | 2018 | 240 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2020 | 534 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 628 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2017 | 150 | 0.030 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 210 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 643 | 0.030 |
Why?
| | Medical Informatics | 1 | 2017 | 101 | 0.030 |
Why?
| | Recovery of Function | 1 | 2020 | 653 | 0.030 |
Why?
| | Embryo, Mammalian | 2 | 2007 | 232 | 0.030 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 327 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 57 | 0.030 |
Why?
| | Nephrectomy | 1 | 2017 | 169 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 669 | 0.030 |
Why?
| | Osteonectin | 1 | 2015 | 2 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 283 | 0.030 |
Why?
| | Palliative Care | 1 | 2022 | 758 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2015 | 20 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 971 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2057 | 0.030 |
Why?
| | Protein Conformation | 1 | 2018 | 934 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2015 | 219 | 0.030 |
Why?
| | Biomarkers | 2 | 2022 | 4149 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2691 | 0.030 |
Why?
| | Genetic Variation | 1 | 2020 | 991 | 0.030 |
Why?
| | Sulfonamides | 1 | 2018 | 513 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 658 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2015 | 332 | 0.030 |
Why?
| | Signal Transduction | 3 | 2019 | 5079 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 2014 | 44 | 0.030 |
Why?
| | Skin | 1 | 2019 | 752 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 698 | 0.030 |
Why?
| | Thoracic Vertebrae | 1 | 2014 | 77 | 0.030 |
Why?
| | Dwarfism, Pituitary | 1 | 2013 | 3 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 2b | 1 | 2013 | 6 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 303 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2015 | 955 | 0.030 |
Why?
| | Models, Molecular | 1 | 2018 | 1570 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2013 | 153 | 0.020 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2757 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2013 | 443 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2013 | 4193 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 2014 | 246 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 399 | 0.020 |
Why?
| | DNA Primers | 1 | 2013 | 515 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 325 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1178 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2006 | 2139 | 0.020 |
Why?
| | Kenya | 1 | 2011 | 118 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2847 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 910 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2837 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2023 | 2654 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 801 | 0.020 |
Why?
| | Protein Binding | 2 | 2007 | 2224 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2009 | 1774 | 0.020 |
Why?
| | Heart Arrest | 1 | 2014 | 339 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2013 | 622 | 0.020 |
Why?
| | Leukemia Virus, Murine | 1 | 2009 | 18 | 0.020 |
Why?
| | Health Surveys | 1 | 2011 | 514 | 0.020 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 91 | 0.020 |
Why?
| | Interferon Regulatory Factors | 1 | 2009 | 39 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2009 | 56 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2009 | 127 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5778 | 0.020 |
Why?
| | Granulocytes | 1 | 2008 | 80 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2009 | 286 | 0.020 |
Why?
| | Water Movements | 1 | 2008 | 31 | 0.020 |
Why?
| | Leupeptins | 1 | 2007 | 10 | 0.020 |
Why?
| | Sewage | 1 | 2008 | 33 | 0.020 |
Why?
| | Connectin | 1 | 2007 | 33 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 510 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 601 | 0.020 |
Why?
| | Ubiquitin | 1 | 2007 | 70 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 324 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1289 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2833 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2008 | 316 | 0.020 |
Why?
| | Hematopoiesis | 1 | 2008 | 192 | 0.020 |
Why?
| | Isoenzymes | 1 | 2007 | 304 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2006 | 119 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2009 | 5757 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2006 | 77 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 156 | 0.020 |
Why?
| | Protein Methyltransferases | 1 | 2006 | 1 | 0.020 |
Why?
| | Logistic Models | 1 | 2011 | 2074 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 434 | 0.020 |
Why?
| | Gene Deletion | 1 | 2007 | 391 | 0.020 |
Why?
| | Veins | 1 | 2006 | 63 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 2071 | 0.020 |
Why?
| | Lung | 1 | 2018 | 4060 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2007 | 844 | 0.010 |
Why?
| | Monocytes | 1 | 2008 | 563 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 657 | 0.010 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 243 | 0.010 |
Why?
| | Cell Movement | 1 | 2009 | 967 | 0.010 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2006 | 136 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2005 | 190 | 0.010 |
Why?
| | Arteries | 1 | 2006 | 269 | 0.010 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2008 | 394 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2007 | 1060 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 861 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 455 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3566 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1502 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2005 | 1457 | 0.010 |
Why?
| | Pregnancy | 1 | 2008 | 6763 | 0.010 |
Why?
|
|
Arnold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|